Understanding 5CLADBA: An Overview For Responsible Research - Revision history

DamonAngas210 at 09:52, 24 May 2026

2026-05-24T09:52:22Z

← Older revision		Revision as of 09:52, 24 May 2026
Line 1:		Line 1:
	~~Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged~~, ~~leading~~ to ~~the structure elucidation of a hydroxy-functional group~~ at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from ~~m/z 366 indicated further dehydrogenation of~~ the ~~ester hydrolysis plus monohydroxylated metabolites. The presence~~ of the ~~product ion m/z 320, likely formed from a loss~~ of ~~carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss~~ of ~~14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.~~<br>~~Fig. 2.~~ <br>4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of ~~mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from~~ the ~~theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto~~ the ~~Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High~~-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, ~~to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC~~-~~C18 analytical column (2.7 μm~~, ~~75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).<br>Fig. 1. <br>Monitoring metabolism of synthetic cannabinoid 4F-~~MDMB-~~BINACA via high~~-~~resolution mass spectrometry assessed in cultured hepatoma cell line~~, ~~fungus, [https://cannabinoidsrc4f~~-~~adb.com/ adb butinaca] liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated~~ as ~~a little ng/mL~~ (0.37–4.1 ng/mL according to the reported cases) of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, ~~30], but no data on high doses of ethanol are available~~. ~~Given that THC and ethanol act on the same receptors~~, ~~data on their simultaneous use may yield important insights in this regard.<br>Fungus C. elegans <br>Methyl (2S~~)~~-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3~~,3-~~dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F~~-ADB), found in numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most of the SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects ~~when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2)~~, ~~where they elicit their main effect~~<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the ~~adb butinaca~~ presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom		Because response suppression may compromise stimulus control, rats failing to complete at least ten responses during the test session were excluded from the analysis of the discriminative stimulus effects of that dose of test compoun<br><br>As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liabilit<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the JWH-210 powder presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br><br>LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl<br><br><br>Although there were reports on the metabolism of 4F-MDMB-BINACA using in-vivo and various in-vitro models, studies were either conducted using small in-vivo sample size such as 1 to 4 samples [5, 29] or in closed environments such as forensic psychiatric wards and prisons . The hepatic cell line HepG2 is often used as an initial screen as it is known to produce high reproducibility results with relatively stable enzyme concentration, although they are limited by the low-level expression of several metabolizing enzymes, including the cytochrome P450 (CYP) class of proteins [17, 18]. In-vitro metabolism studies are generally used to complement these data using perfused organs, tissue or cell cultures and microsomal preparations amongst which pooled human liver microsomes (HLM) have been frequently used to elucidate metabolism of SCBs [12,13,14,15,16]. Since most SCBs are found extensively in metabolized forms in urine, the identification of metabolites is of vital importance for forensic and clinical toxicologists. Identifying SCB intake and its correlating specific adverse effects require rapid elucidation of these SCBs. The proliferation of SCBs has become a global challenge as new compounds are rapidly introduced into the illegal drug market to evade existing drug laws.<br>Fig.

DamonAngas210 at 09:36, 24 May 2026

2026-05-24T09:36:50Z

← Older revision		Revision as of 09:36, 24 May 2026
Line 1:		Line 1:
	~~Figure 1. <br>Each training session lasted a maximum of 10 min~~, and ~~the rats could earn up to 20 food pellets. Thirty minutes prior~~ to the ~~training sessions, rats received an injection~~ of ~~either vehicle or Δ9~~-~~THC and were subsequently placed in~~ the ~~behavior~~-~~testing chambers~~, ~~where food~~ (~~45-mg food pellets; Bio-Serve~~, ~~Frenchtown, NJ~~) ~~was available as~~ a ~~reinforcer for every ten responses (FR10) on a designated injection appropriate lever~~. ~~A houselight was centered over~~ the ~~hopper close to~~ the ~~ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty~~-~~four male Sprague-Dawley rats were obtained from Envigo~~ (~~Houston~~, TX). ~~Male ND4 Swiss–Webster mice were obtained from Envigo (Houston~~, ~~TX) at approximately 8 weeks~~ of ~~age and maintained in~~ the ~~University~~ of ~~North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin~~<br><br>~~<br>Moreover, a study conducted in~~ the ~~United Kingdom investigated components of e~~-~~liquids in 112~~ samples ~~originating~~ from ~~prisoners, teenagers~~ and ~~test purchases~~ of ~~commercially available e~~-~~cigarettes taken between 2014~~ and ~~2021~~ . ~~This is~~ the ~~first case report that describes the toxicological symptoms~~ of ~~vaping ADB~~-~~BUTINACA. Results~~ of the ~~DOA test~~ (~~including testing for amphetamines~~, ~~methamphetamines, barbiturates, benzodiazepines~~, ~~cocaine~~, ~~methadone~~, ~~opioids, cannabis, tricyclic antidepressants~~) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.<br>~~Data availabili<br>~~<br>~~There is indication that at least some~~ of ~~the first-generation~~ synthetic ~~cannabinoids act at receptors other than~~ cannabinoid ~~CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F~~-MDMB-~~PINACA~~, ~~was found to activate midbrain dopamine neurons~~, ~~but not serotonin neurons (Asaoka et al~~.~~, 2016<br><br><br>Test 2 was performed everyday~~ for ~~5 days after consecutive administration~~ of ~~the substances, including negative (vehicle)~~ and ~~positive~~ (~~methamphetamine) controls~~. ~~After the last administration, the first trial was performed~~. ~~Morris water maze test was performed~~ to ~~evaluate~~ the ~~changes~~ of ~~learning~~ and ~~memory function through administration~~ of ~~the test substances~~. ~~Generally, neurotoxicity~~ of a ~~substance is evaluated by animal behavioral aspects~~, i.~~e. functional observation battery (FOB) tests (O’Callaghan et al~~., ~~2014)~~. ~~Our results suggest~~ that ~~JWH-081~~ and ~~JWH-210~~ may ~~[https://cannabinoidsrc4f-adb.com/ sneak a peek at~~ this ~~website] be neurotoxic substances through changing neuronal cell damages, especially in the core shell part of nucleus accumbens~~.<br>~~About Powder JWH-2~~<br>~~<br><br>The current study indicates that the test compounds produce locomotor depression similar to that of Δ9~~-~~THC~~, ~~and fully substitute for the discriminative stimulus effects of Δ9~~-~~THC. In summary, these 5F~~-MDMB-~~PINACA~~, MDMB-~~CHIMICA, MDMB~~-~~FUBINACA,~~ ADB~~-FUBINACA~~, ~~and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled~~ in ~~a similar fashion~~. ~~Much~~ of the ~~in vivo sneak~~ a ~~peek at this website testing~~ of ~~the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like~~ effects ~~or like the present study, focused on their abuse liability~~. ~~There is indication that at least some of the first-generation synthetic~~ cannabinoids ~~act~~ at ~~receptors other than~~ cannabinoid CB1 and CB2 ~~(Wiley et al., 2016~~), ~~and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016~~<br><br><br>~~As synthetic cannabinoid receptor agonists~~ (~~SCRA~~) ~~are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests~~. He confirmed ~~that he had been vaping~~ an ~~electronic cigarette (~~e-cigarette~~) earlier that day just~~ before the onset of his symptoms. ~~Metabolic acidosis (1/3, 0/7)~~ and ~~respiratory acidosis (1/3, 0/7), All 10 patients recovered~~ with ~~supportive care~~, ~~including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected~~, ~~while in seven other substances~~ of ~~misuse were also detected including other~~ SCRA~~, opioids, benzodiazepines cocaine and pregabali~~<br><br>~~<br>In~~ the ~~present study, we performed various methods based on animal behavioral testing including FOB test~~ for ~~general behavioral observation, rotarod test, locomotor activity test for motor function evaluation~~, and ~~water~~-~~maze test for learning/memory evaluation~~. ~~Known for its stability~~ and ~~consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory~~-~~based analytical studies. In this study, histopathological evaluation was performed to confirm~~ the ~~possibility of neurotoxicity of~~ the ~~tested substances by hematoxylin and eosin staining method from collected brain samples~~. In the ~~present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH~~-~~081~~ and ~~JWH~~-~~210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses~~ (0.1~~, 1, 5 mg/kg~~). ~~Selecting powder JWH~~-~~210 demands careful evaluation~~ of ~~purity~~, ~~legality, and supplier credibility. Prices for research~~-~~grade JWH~~-~~210 vary significantly based~~ on ~~quantity, purity~~, and ~~vendor complianc~~		Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.<br>Fig. 2. <br>4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).<br>Fig. 1. <br>Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, [https://cannabinoidsrc4f-adb.com/ adb butinaca] liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according to the reported cases) of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard.<br>Fungus C. elegans <br>Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F-ADB), found in numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most of the SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2), where they elicit their main effect<br><br><br>High resolution mass spectrometry such as LC-QTOF-MS allows the detection and identification of a broad spectrum of recreational drugs, including new psychoactive substances. A point-of-care drugs of abuse (DOA) test was initially performed on the urine of the patient. He confirmed drinking 750 ml energy drink without any further consumption of food and using an e-cigarette from Gaziantep, Turkey 10 seconds before the onset of his first symptoms. He usually smokes a pack of cigarettes a day and sometimes smokes e-cigarettes. Combined with non-specific, transient symptoms, clinical recognition of SCRA intoxication is challenging .<br>Data availability <br>The intensity is plotted against the retention time for both chromatograms, demonstrating the adb butinaca presence and elution profiles of nicotine and ADB-BUTINACA in the analysed vape liquid sample. LC-QTOF-MS Chromatograms of Nicotine (Top) and ADB-BUTINACA (Bottom) in the Vape Liquid used by the patient. The LC-QTOF-MS analysis showed that the e-liquid contained nicotine and ADB-BUTINACA (Fig. 1). Because the point-of-care DOA test is generally not able to detect synthetic recreational drug substances, the liquid of the e-cigarette was thereafter screened using liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) on the Waters™ Xevo G3 QTOF MS system. After eating a light meal and drinking caffeinated sports drinks at the ER, the nausea complaints of the patient were reduced and the patient was discharged hom

Norris9662 at 09:36, 24 May 2026

2026-05-24T09:36:13Z

← Older revision		Revision as of 09:36, 24 May 2026
Line 1:		Line 1:
	Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br><br>~~Product ions detected at m/z 302~~, ~~217~~, and ~~145 (B2) confirmed that tert~~-~~leucine~~ and ~~indazole moieties remained unchanged, leading to~~ the ~~structure elucidation~~ of ~~a hydroxy~~-~~functional group at the 4-position~~ of the ~~butyl side chain by oxidative defluorination. The product ion m/z 336~~ (~~loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion~~, ~~m/z 364 (B14~~, ~~B5/B6~~) ~~had~~ a ~~loss~~ of ~~2 Da from m/z 366 indicated further dehydrogenation~~ of the ~~ester hydrolysis plus monohydroxylated metabolites~~. ~~The presence~~ of the ~~product ion m/z 320, likely formed from a loss~~ of ~~carbon dioxide, indicated monohydroxylation at~~ the ~~tert~~-~~leucine in B8~~ (~~m/z 219~~), ~~butyl side chain in B9 (m/z 145)~~ and ~~indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed~~ a ~~loss of 14 Da explaining~~ the ~~hydrolysis of methyl ester from 4F~~-MDMB-~~BINACA~~.<br>~~Fig. 2.~~ <br>~~The precursor ion m/z 396 (B10, B12/B15)~~ was ~~32 Da higher than~~ the ~~parent drug~~, ~~4F-MDMB-BINACA, suggesting the addition of two hydroxy groups~~. ~~All~~ the ~~below explanations for transformations into metabolites are based on~~ the ~~data shown in Fig~~. ~~Metabolites were identified according~~ to ~~their precursor ions, product ions,~~ and ~~fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites~~ of ~~drugs relied heavily on~~ the ~~use~~ of ~~whole~~ animal ~~model systems, which are expensive, limited by drug administration amount~~, ~~influenced by species variation and faced by many ethical issues~~. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.~~<br>Fig~~. 1. ~~<br>Monitoring metabolism of synthetic cannabinoid 4F~~-~~MDMB~~-~~BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus,~~ [https://cannabinoidsrc4f-adb.com/ ~~4F ADB~~] ~~liver microsomes and confirmed using urine samples The threshold for fatal overdose~~ of ~~combined use of SCRAs and ethanol can be estimated as a little ng/mL (0~~.~~37–4.1 ng/mL according~~ to ~~the reported cases)~~ of ~~SCRA~~ and ~~1.5–2.5 g/L~~ of ~~ethanol~~. ~~The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol~~, ~~because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis~~ and ~~acute kidney injury evolving into multi~~-~~organ failure 11 days after hospital admission . Studies~~ have ~~found no unequivocal synergistic effect between THC~~ and ~~ethanol~~ at ~~low or moderate ethanol doses [29, 30], but no data on high doses~~ of ~~ethanol are available. Given that THC and ethanol act~~ on the ~~same receptors~~, ~~data~~ on their ~~simultaneous use may yield important insights in this regard~~.~~<br>Fungus C. elegans <br>Concentrations~~ of 4F-~~MDMB-BINACA in the postmortem blood samples were 2.50~~ and 2.~~34 ng/mL~~, ~~which are in line with published data. Although~~ the ~~lethal dose of 4F~~-MDMB-~~BINACA is unknown~~, ~~its concentration in postmortem blood samples~~ was found to ~~range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease~~, ~~the SCRA concentration in the postmortem blood was less than 1 ng/mL~~ . ~~Concentrations of SCRAs in postmortem cases cover a wide range ; however~~, ~~some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20~~<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>~~Inclusion in an NLM database does not imply endorsement of~~, ~~or agreement with~~, ~~the contents~~ by ~~NLM or the National Institutes of Health~~. ~~It is illegal~~ to ~~sell, distribute, supply, transport or trade~~ the ~~pharmaceutical drug under~~ the ~~Psychoactive Substances Act 2016~~. ~~The corresponding indole core analogue~~, ~~4F-MDMB-BICA~~ (4F-~~MDMB~~-~~BUTICA~~), ~~has also been widely sold as a designer drug by chemical providers on the internet~~, ~~first being identified in May 2020~~. ~~It has been used as an active ingredient in synthetic cannabis products~~ and ~~sold as a designer drug since late 2018~~. 4F-~~MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole~~-based ~~synthetic cannabinoid from the indazole-3-carboxamide family.<br> Fig.~~		Figure 1. <br>Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br><br>Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.<br>Data availabili<br><br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016<br><br><br>Test 2 was performed everyday for 5 days after consecutive administration of the substances, including negative (vehicle) and positive (methamphetamine) controls. After the last administration, the first trial was performed. Morris water maze test was performed to evaluate the changes of learning and memory function through administration of the test substances. Generally, neurotoxicity of a substance is evaluated by animal behavioral aspects, i.e. functional observation battery (FOB) tests (O’Callaghan et al., 2014). Our results suggest that JWH-081 and JWH-210 may [https://cannabinoidsrc4f-adb.com/ sneak a peek at this website] be neurotoxic substances through changing neuronal cell damages, especially in the core shell part of nucleus accumbens.<br>About Powder JWH-2<br><br><br>The current study indicates that the test compounds produce locomotor depression similar to that of Δ9-THC, and fully substitute for the discriminative stimulus effects of Δ9-THC. In summary, these 5F-MDMB-PINACA, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA have similar abuse liability as Δ9-tetrahydrocannabinol and should be controlled in a similar fashion. Much of the in vivo sneak a peek at this website testing of the synthetic cannabinoid compounds have been pre-clinical studies focused on their cannabinoid-like effects or like the present study, focused on their abuse liability. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation. Known for its stability and consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc

DamonAngas210 at 09:26, 24 May 2026

2026-05-24T09:26:39Z

← Older revision		Revision as of 09:26, 24 May 2026
Line 1:		Line 1:
	LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at ~~this forum, 7.~~8 ~~% vaped SCRAs . About 15 %~~ of ~~individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines~~ and ~~hallucinogens to~~ the ~~new psychoactive substances~~ (~~NPS~~) ~~that are currently developed at high speed.~~<br>~~Data availabili~~<br><br>~~Fig. 2. <br>Separation~~ of ~~compounds was performed on~~ a ~~2.1 mm×100 mm, 1.7 [https://cannabinoidsrc4f~~-~~adb~~.~~com~~/ ~~adb butinaca] μm particle size ACQUITY Torus™ DIOL analytical column~~ (~~Waters~~) ~~with guard cartridge~~. ~~Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system~~ (~~Waters~~) ~~coupled with~~ a ~~Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters)~~. ~~During~~ the ~~death scene examination~~, ~~multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles~~, ~~an unopened box of nebivolol~~-~~containing drug~~, and ~~18 g of unrecognizable herbal residue~~ in a ~~cigarette box~~.<br>~~Victim B also brought "something resembling a drug" (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco~~. The ~~half-maximal effective concentration~~ (~~EC50~~) of 4F-MDMB-BINACA ~~is 5~~.~~69 nM (2~~.~~76–11.0 nM) on CB1~~, and ~~0.69 nM~~ (0.~~30–1~~.~~56 nM)~~ on ~~CB2~~, in ~~vitro half~~-~~life (t1/2) is 10.27 min . It is usually available as a powder~~, ~~liquid (vapor fluid)~~, ~~or herbal plant mixtur~~<br><br>~~<br>Tremors were observed~~ in ~~mice 30 minutes following 1 mg~~/~~kg AMB~~-~~FUBINACA in the present study~~. ~~Pretreatment times~~ and ~~dose ranges~~ for ~~the drug discrimination assay were selected based on the time~~ of ~~peak depression in the locomotor activity assay in mice. Average potency~~ of ~~the discriminative stimulus effects of early compounds was~~ 0.~~81±0~~.~~17 mg~~/~~kg (Gatch et al., 2014~~)~~, whereas the potency~~ of ~~a recent set was 0~~.~~09±0~~.~~03 mg~~/~~kg (Gatch et al~~.~~, 2018),~~ and ~~the potency~~ of the ~~current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have~~ a ~~greater abuse liability~~, and ~~long~~-~~acting compounds pose problems of long-acting adverse effects and interactions with other drugs~~. ~~The duration of action of the synthetic cannabinoids tested using the 8-h protocol~~ have ~~varied widely~~, ~~with some producing a duration of action~~ no ~~longer than 1 h, others producing a duration~~ of ~~action between 1–2 h~~, ~~and others lasting more than 2 h~~. ~~There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound~~<br><br>~~<br>LC~~-~~QTOF~~-~~MS represents a significant advancement~~ in the ~~field of drug detection, offering higher sensitivity, specificity,~~ and ~~a broader spectrum of detectable substances~~. ~~Despite all negative results~~ in the ~~point~~-of-~~care test for recreational drugs~~, the ~~liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that~~ the ~~liquid of~~ the ~~e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid~~. ~~We report~~ a ~~27-year-old man who was admitted to the emergency room because~~ of ~~sudden adb butinaca headache, nausea, vertigo~~, ~~red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl~~<br><br><br>~~These~~ synthetic ~~cannabinoids act directly at~~ cannabinoid ~~CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol~~ (~~Δ9-THC~~) ~~found in marijuana~~, ~~but~~ have ~~different chemical structures unrelated~~ to Δ9-~~THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014~~). ~~Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol~~ (3 mg/~~kg, 30-min pretreatment~~)~~. 5F-MDMB-PINACA~~ (~~also known as 5F-ADB~~, ~~5F-ADB-PINACA~~), ~~MDMB-CHIMICA, MDMB-FUBINACA~~, ADB-~~FUBINACA~~, ~~and AMB-FUBINACA (~~also ~~known as FUB-AMB~~, ~~MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit~~<br><br><br>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to adb butinaca quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ~~ideal choice for laboratories that prioritize both efficiency and compliance with research standards.<br>Key Features and Specifications to Evaluate <br>In case~~ of ~~cannabis~~ or ~~Δ9-tetrahydrocannabinol, there are many adb butinaca previous studies regarding~~ with ~~their dependence potential and neurotoxicity (Cororan~~, ~~et al~~., ~~1974; Harris~~, ~~et al.~~, ~~1974; Leite and Culini, 1974; Hutcheson, et al~~., ~~1998~~)~~. After administering test substances once every other day for 10 days~~, ~~brain samples of mice were collected~~, ~~especially at nucleus accumbens and hippocampus regions~~. ~~Drug was administered 5 times every other day,~~ and ~~the first trial was performed 2 h after the last administration~~.~~<br>How to Choose Powder JWH~~-~~210 <br>This dual~~-~~use nature underscores~~ the ~~importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH~~-~~210 to distinguish between legal and illegal compounds in seized materials~~. ~~For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution~~. ~~With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based researc~~		Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br><br>Product ions detected at m/z 302, 217, and 145 (B2) confirmed that tert-leucine and indazole moieties remained unchanged, leading to the structure elucidation of a hydroxy-functional group at the 4-position of the butyl side chain by oxidative defluorination. The product ion m/z 336 (loss of methyl ester moiety) further confirmed the presence of dihydroxylated metabolites. The precursor ion, m/z 364 (B14, B5/B6) had a loss of 2 Da from m/z 366 indicated further dehydrogenation of the ester hydrolysis plus monohydroxylated metabolites. The presence of the product ion m/z 320, likely formed from a loss of carbon dioxide, indicated monohydroxylation at the tert-leucine in B8 (m/z 219), butyl side chain in B9 (m/z 145) and indazole moiety in B13 (m/z 161). The precursor ion, m/z 350 showed a loss of 14 Da explaining the hydrolysis of methyl ester from 4F-MDMB-BINACA.<br>Fig. 2. <br>The precursor ion m/z 396 (B10, B12/B15) was 32 Da higher than the parent drug, 4F-MDMB-BINACA, suggesting the addition of two hydroxy groups. All the below explanations for transformations into metabolites are based on the data shown in Fig. Metabolites were identified according to their precursor ions, product ions, and fragmentation patterns (Fig. 1). Traditional in-vivo metabolism studies to generate human metabolites of drugs relied heavily on the use of whole animal model systems, which are expensive, limited by drug administration amount, influenced by species variation and faced by many ethical issues. Eight in-vivo metabolites tentatively identified were mainly products of ester hydrolysis with or without additional dehydrogenation, N-dealkylation, monohydroxylation and oxidative defluorination with further oxidation to butanoic acid.<br>Fig. 1. <br>Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, [https://cannabinoidsrc4f-adb.com/ 4F ADB] liver microsomes and confirmed using urine samples The threshold for fatal overdose of combined use of SCRAs and ethanol can be estimated as a little ng/mL (0.37–4.1 ng/mL according to the reported cases) of SCRA and 1.5–2.5 g/L of ethanol. The reported cases and reviews of the scientific literature suggest a possible synergistic effect between SCRAs and ethanol, because their combined use clearly increases their toxicity. The victim died due to severe necrotizing pancreatitis and acute kidney injury evolving into multi-organ failure 11 days after hospital admission . Studies have found no unequivocal synergistic effect between THC and ethanol at low or moderate ethanol doses [29, 30], but no data on high doses of ethanol are available. Given that THC and ethanol act on the same receptors, data on their simultaneous use may yield important insights in this regard.<br>Fungus C. elegans <br>Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. It is illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the Psychoactive Substances Act 2016. The corresponding indole core analogue, 4F-MDMB-BICA (4F-MDMB-BUTICA), has also been widely sold as a designer drug by chemical providers on the internet, first being identified in May 2020. It has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4F-MDMB-BINACA (also known as MDMB-4F-BINACA using systematic EMCDDA nomenclature or 4F-MDMB-BUTINACA) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family.<br> Fig.

DamonAngas210 at 09:26, 24 May 2026

2026-05-24T09:26:08Z

← Older revision		Revision as of 09:26, 24 May 2026
Line 1:		Line 1:
	~~When clinical presentation~~ and~~/or initial DOA testing results are inconclusive, additional testing with LC-~~QTOF-MS ~~can be valuable~~ and ~~is recommended. SCRAs~~ and ~~other NPS may not be detected by point-~~of~~-care DOA tests~~. ~~In this case, the point~~-of-~~care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br><br>Thirty minutes prior to the training sessions~~, ~~rats received an injection~~ of ~~either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers~~, ~~where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever~~. ~~A houselight was centered over~~ the ~~hopper close~~ to the ~~ceiling~~ and ~~was illuminated only when~~ the ~~levers were active~~. ~~Each dose range included doses that were without effect to those producing~~ at ~~least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston~~, ~~TX)~~. ~~4F ADB Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately~~ 8 ~~weeks~~ of ~~age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility~~ for ~~two weeks prior to testin<br><br>In both tests, a group of mice were treated with negative control (vehicle, 1 mg/kg, i~~.p.), ~~positive control (methamphetamine, 1 mg/kg~~, ~~i.p.)~~, ~~or one of~~ the ~~three doses of test~~ substances (0.~~1, 1, 5 mg/kg, i.p.) once every other day for 10 day~~<br><br><br>~~All~~ of ~~the~~ compounds ~~tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al~~., ~~2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of~~ 1.~~33 mg/kg were observed within 10 min following administration and peak depressant effects were~~ [https://cannabinoidsrc4f-adb.com/ ~~4F ADB~~] ~~observed between 0–30 min~~. ~~Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br><br>§~~ (3) ~~of the Hungarian act of Forensic Experts~~ (~~2016.XXIX~~)~~, the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission~~. ~~These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused~~ the death ~~of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available~~ in ~~the scientific literature about the possible effects~~ of ~~the combined consumption of SCRAs~~ and ~~ethanol. Several case reports describe that the presence~~ of a ~~little ng/mL (0~~.~~37–4.1) of SCRAs and~~ a ~~high—but not lethal—concentration of ethanol~~ (~~1.45–2.7 g/L~~) ~~directly and exclusively contributed to the death of the victim [24–27]~~ (~~Table 2~~). The ~~fact that 4F~~-~~MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism~~ of ~~SCRAs [11, 14, 22], but also suggests that the victims consumed~~ 4F-MDMB-BINACA ~~shortly before their death<br><br>Figure 1~~. ~~<br>Each training session lasted a maximum of 10 min~~, and ~~the rats could earn up to 20 food pellets~~. ~~Thirty minutes prior to the training sessions~~, ~~rats received an injection of either vehicle or Δ9-THC and were subsequently placed~~ in ~~the behavior~~-~~testing chambers, where food~~ (~~45-mg food pellets; Bio-Serve, Frenchtown, NJ~~) ~~was~~ available as a ~~reinforcer for every ten responses~~ (~~FR10~~) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br>~~4. Drugs~~ <br>~~In general,~~ the locomotor ~~depressant and~~ discriminative stimulus effects ~~have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210~~ (Gatch et al., ~~2016~~), ~~and 5F-AMB produced sustained vocalization and convulsions in rats~~ (Gatch et al., 2018)~~. All~~ of the ~~synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9~~-~~THC. Subsequently~~, a ~~one~~-~~way analysis~~ of ~~variance was conducted on horizontal activity counts for the 30~~-~~min period~~ of ~~maximal effect, and planned comparisons were conducted for each dose against~~ the ~~vehicle control~~ using ~~single degree~~-of~~-freedom F tests. A two-way analysis of variance~~, ~~with dose as~~ a between ~~groups factor~~ and ~~time as a within subject factor, was conducted on horizontal activity counts/10 min interval~~. ~~Locomotor activity in mice was tested~~ to ~~screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times~~ of ~~peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to~~ synthetic cannabinoids ~~known to have substantial abuse liability and act at the CB1 receptor.~~<br>~~Michael B Gatch~~ <br>~~Substantial depressant effects were observed within~~ the ~~first 10 min~~, and ~~maximal depression was observed between 0–30 min following administration~~. ~~Tremors were observed 30 minutes following 1 mg/kg AMB~~-~~FUBINACA in 3~~ of ~~8 mice~~ (~~data not shown~~)~~. Substantial depressant effects were observed within~~ the ~~first 10 min~~, ~~and maximal depression~~ was ~~observed between 10–40 min and lasted up to 2.5~~ to ~~3 h at~~ the ~~4F ADB highest dose tested (0.5 mg/kg)~~.<br>~~Figure 1.~~ <br>~~There is indication that at least some of the first-generation~~ synthetic cannabinoids act at ~~receptors other than~~ cannabinoid CB1 and CB2 (~~Wiley et al., 2016~~), ~~and a compound from the present study, 5F~~-~~MDMB-PINACA~~, ~~was found to activate midbrain dopamine neurons~~, ~~but not serotonin neurons~~ (~~Asaoka~~ et al., ~~2016~~). ~~As previously mentioned, all of the compounds~~ tested in ~~the present study~~ (MDMB-PINACA, MDMB-~~CHMICA~~, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) ~~act~~ as ~~agonists at CB1 receptors~~ (~~Banister~~ et al., ~~2015~~, ~~2016~~; ~~Gamage~~ et al., ~~2018~~), ~~which suggests these compounds will produce Δ9-THC-like effects~~, ~~including abuse liability~~. ~~Tremors were not observed following AMB-FUBINACA during the drug discrimination study~~, ~~but~~ the ~~maximum dose tested~~ was ~~only 0~~.~~1 mg/kg~~, ~~which is 10~~-~~fold lower than the dose that produced tremors~~ in ~~the mic~~		LC separates the urine or blood sample and QTOF-MS provides high-resolution and accurate mass measurements for precise identification and structural elucidation of compounds. The LC-QTOF-MS method offers a more comprehensive and sensitive approach for drug detection, covering hundreds of recreational drugs, including NPS. Besides increasing the temperature to enlarge the drug aerolisation and bioavailability, one can elevate the flow rate of air through the e-cigarette and/or add a diluent . Of all e-cigarette users registered at this forum, 7.8 % vaped SCRAs . About 15 % of individuals registered at forums for drug users such as erowid.org who vaped cannabis have also vaped SRCAs. SCRAs belong, together with synthetic opioids, cathinones, amphetamines and hallucinogens to the new psychoactive substances (NPS) that are currently developed at high speed.<br>Data availabili<br><br>Fig. 2. <br>Separation of compounds was performed on a 2.1 mm×100 mm, 1.7 [https://cannabinoidsrc4f-adb.com/ adb butinaca] μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge. Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters) coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). During the death scene examination, multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles, an unopened box of nebivolol-containing drug, and 18 g of unrecognizable herbal residue in a cigarette box.<br>Victim B also brought "something resembling a drug" (unrecognizable by Witness A) from his cousin (Witness B) in a cigarette box and mixed this substance with their tobacco. The half-maximal effective concentration (EC50) of 4F-MDMB-BINACA is 5.69 nM (2.76–11.0 nM) on CB1, and 0.69 nM (0.30–1.56 nM) on CB2, in vitro half-life (t1/2) is 10.27 min . It is usually available as a powder, liquid (vapor fluid), or herbal plant mixtur<br><br><br>Tremors were observed in mice 30 minutes following 1 mg/kg AMB-FUBINACA in the present study. Pretreatment times and dose ranges for the drug discrimination assay were selected based on the time of peak depression in the locomotor activity assay in mice. Average potency of the discriminative stimulus effects of early compounds was 0.81±0.17 mg/kg (Gatch et al., 2014), whereas the potency of a recent set was 0.09±0.03 mg/kg (Gatch et al., 2018), and the potency of the current set is 0.05±0.01 mg/kg. Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compound<br><br><br>LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden adb butinaca headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly availabl<br><br><br>These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<br><br><br>In summary, JWH-210 Chemical Powder stands out as a high-quality research compound designed for professionals who demand accuracy, consistency, and reliability. This commitment to adb butinaca quality makes it a trusted option for professionals who require dependable compounds for their work. From sourcing raw materials to final packaging, every stage of the process is monitored to ensure compliance with laboratory-grade expectations. This makes it an ideal choice for laboratories that prioritize both efficiency and compliance with research standards.<br>Key Features and Specifications to Evaluate <br>In case of cannabis or Δ9-tetrahydrocannabinol, there are many adb butinaca previous studies regarding with their dependence potential and neurotoxicity (Cororan, et al., 1974; Harris, et al., 1974; Leite and Culini, 1974; Hutcheson, et al., 1998). After administering test substances once every other day for 10 days, brain samples of mice were collected, especially at nucleus accumbens and hippocampus regions. Drug was administered 5 times every other day, and the first trial was performed 2 h after the last administration.<br>How to Choose Powder JWH-210 <br>This dual-use nature underscores the importance of responsible sourcing and strict adherence to legal frameworks. Forensic labs, public health researchers, and customs officials use authentic samples like JWH-210 to distinguish between legal and illegal compounds in seized materials. For those seeking a dependable compound for analytical purposes, JWH-210 Chemical Powder provides a trusted and effective solution. With its carefully controlled production process, stable composition, and secure packaging, it remains a valuable resource for laboratory-based researc

ClaudetteCorones at 12:14, 22 May 2026

2026-05-22T12:14:35Z

← Older revision		Revision as of 12:14, 22 May 2026
Line 1:		Line 1:
	All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ ~~JWH-210 powder~~] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br><br>~~Acute kidney damage and even kidney failure have been reported following use~~ of ~~synthetic cannabinoids~~ (~~Davidson, et al~~., ~~2017)~~. ~~One recent study has looked at other mechanisms~~ of ~~action~~ in ~~some~~ of the ~~older synthetic cannabinoids~~ and ~~reported~~ that ~~some produced varying amounts~~ of ~~activity at sites which are related to cardiotoxicity~~ and ~~heart disease~~ (~~Wiley et al~~.~~, 2016~~). It is ~~not known whether~~ the ~~increased toxicity is due only to activation~~ of ~~CB1 cannabinoid receptors more strongly than Δ9-THC or whether these "super-strength" cannabinoids produce effects at other receptors. A major cause~~ of ~~concern is~~ that ~~some of~~ the ~~more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than the older synthetics (Tai and Fantegrossi, 2017~~<br><br><br>~~These synthetic cannabinoids act JWH-210 powder directly at cannabinoid CB1~~ and ~~CB2 receptors as does Δ9-tetrahydrocannabinol (~~Δ9-THC~~) found~~ in ~~marijuana~~, ~~but have different chemical structures unrelated to Δ9~~-~~THC~~, ~~different metabolism~~, ~~and often greater toxicity~~ (~~Fantegrossi et al~~.~~, 2014)~~. ~~Discriminative stimulus effects~~ were ~~tested in rats trained~~ to ~~discriminate Δ9~~-~~tetrahydrocannabinol~~ (~~3 mg/kg~~, ~~30-min pretreatment~~). ~~5F-MDMB-PINACA~~ (~~also known as 5F-ADB~~, ~~5F-ADB-PINACA~~)~~, MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA,~~ and ~~AMB-FUBINACA~~ (~~also known as FUB-AMB, MMB-FUBINACA~~) ~~were tested~~ for ~~in vivo cannabinoid-like effects~~ to ~~assess their abuse liabilit~~<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the ~~JWH-210 powder~~ highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.<br>Michael B Gat<br><br><br>Separation of compounds was performed on a 2.1 mm×100 mm, 1.7 JWH-210 powder μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge. Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters) coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). During the death scene examination, multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles, an unopened box of nebivolol-containing drug, and 18 g of unrecognizable herbal residue in a cigarette box.<br>Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author		When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br><br>Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). 4F ADB Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br>In both tests, a group of mice were treated with negative control (vehicle, 1 mg/kg, i.p.), positive control (methamphetamine, 1 mg/kg, i.p.), or one of the three doses of test substances (0.1, 1, 5 mg/kg, i.p.) once every other day for 10 day<br><br><br>All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ 4F ADB] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br><br>§ (3) of the Hungarian act of Forensic Experts (2016.XXIX), the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused the death of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol. Several case reports describe that the presence of a little ng/mL (0.37–4.1) of SCRAs and a high—but not lethal—concentration of ethanol (1.45–2.7 g/L) directly and exclusively contributed to the death of the victim [24–27] (Table 2). The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death<br><br>Figure 1. <br>Each training session lasted a maximum of 10 min, and the rats could earn up to 20 food pellets. Thirty minutes prior to the training sessions, rats received an injection of either vehicle or Δ9-THC and were subsequently placed in the behavior-testing chambers, where food (45-mg food pellets; Bio-Serve, Frenchtown, NJ) was available as a reinforcer for every ten responses (FR10) on a designated injection appropriate lever. A houselight was centered over the hopper close to the ceiling and was illuminated only when the levers were active. Each dose range included doses that were without effect to those producing at least 50% depression compared to vehicle control. Twenty-four male Sprague-Dawley rats were obtained from Envigo (Houston, TX). Male ND4 Swiss–Webster mice were obtained from Envigo (Houston, TX) at approximately 8 weeks of age and maintained in the University of North Texas Health Science Center (UNTHSC) animal facility for two weeks prior to testin<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the 4F ADB highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mic

Norris9662 at 08:13, 18 May 2026

2026-05-18T08:13:05Z

← Older revision		Revision as of 08:13, 18 May 2026
Line 1:		Line 1:
	All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ ~~find more~~] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br>~~4. Drugs~~ <br>~~Short-onset~~, ~~short-acting compounds have a greater abuse liability~~, ~~and long-acting compounds pose problems of long-acting adverse effects and interactions with~~ other ~~drugs. The duration~~ of action of the synthetic cannabinoids ~~tested using the 8-h protocol have varied widely, with~~ some ~~producing a duration~~ of ~~action no longer than 1 h~~, ~~others producing a duration~~ of ~~action between 1–2 h, and others lasting~~ more than ~~2 h~~. ~~There seems to be a trend~~ of ~~newer~~ synthetic cannabinoids ~~being~~ more ~~potent~~ than ~~earlier compounds. All of~~ the ~~compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids~~ (~~see review by Wiley et al.~~, 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br><br>As synthetic cannabinoid ~~receptor agonists~~ (~~SCRA~~) ~~are gaining popularity globally~~, ~~clinicians~~ have to ~~understand that intoxication caused by vaping SCRA is not detected by commonly available tests~~. ~~He confirmed that he had been vaping an electronic cigarette (e-cigarette~~) ~~earlier that day just before the onset of his symptoms~~. ~~Metabolic acidosis~~ (1/3~~, 0~~/~~7) and respiratory acidosis (1/3~~, ~~0/7~~)~~, All 10 patients recovered with supportive care, including intubation and ventilation for one case~~. ~~In 3 cases ADB~~-~~BUTINACA was the only substance detected, while in seven other substances of misuse were~~ also ~~detected including other SCRA~~, ~~opioids, benzodiazepines cocaine and pregabali<br><br><br>A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point~~-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), ~~gamma~~-~~hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e~~-~~cigarettes~~, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours .<br>Data availability <br>Moreover, a study conducted in the United Kingdom investigated components of e-~~liquids in 112 samples originating from prisoners~~, ~~teenagers~~ and ~~test purchases of commercially available e~~-~~cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB~~-~~BUTINACA. Results of the DOA test (including testing for amphetamines~~, ~~methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants~~) were ~~available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB~~-~~BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.~~<br>~~Data availabili~~<br><br>~~<br>Synthetic cannabinoids~~ have ~~consistently~~ been ~~shown to~~ produce ~~discriminative stimulus~~ effects ~~similar to those find more of Δ9~~-~~THC~~ (~~Bannister and Connor~~, ~~2018~~), and ~~MDMB~~-~~FUBINACA fully substituted for Δ9-THC~~ (~~Gamage~~ et al., 2018). ~~The chemical structures~~ of the ~~recent~~ synthetic cannabinoids ~~are unlike that~~ of Δ9-THC, ~~but are largely based~~ on the ~~structure~~ of ~~older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity~~ and ~~produced discriminative stimulus effects similar to those of Δ9~~-~~THC, which suggests they may have abuse liability similar to that~~ of Δ9-~~THC~~. ~~Subsequent testing identified 5F~~-~~ADB to have been present in~~ a ~~total of ten people who had died from unexplained drug overdoses in Japan~~ between ~~September 2014~~ and ~~December 2014~~. ~~AMB~~-~~FUBINACA produced tremors~~ and ~~may be~~ of ~~increased risk in human recreational users~~.<br>Michael B Gatch <br>~~Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg.~~ Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 ~~shows average horizontal activity counts~~/10 ~~min as~~ a ~~function~~ of ~~time~~ (~~0–4 h~~) and ~~dose~~ of Δ9-TH		All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br><br>Acute kidney damage and even kidney failure have been reported following use of synthetic cannabinoids (Davidson, et al., 2017). One recent study has looked at other mechanisms of action in some of the older synthetic cannabinoids and reported that some produced varying amounts of activity at sites which are related to cardiotoxicity and heart disease (Wiley et al., 2016). It is not known whether the increased toxicity is due only to activation of CB1 cannabinoid receptors more strongly than Δ9-THC or whether these "super-strength" cannabinoids produce effects at other receptors. A major cause of concern is that some of the more recently seen synthetic cannabinoids are more likely to produce extremely toxic effects than the older synthetics (Tai and Fantegrossi, 2017<br><br><br>These synthetic cannabinoids act JWH-210 powder directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit<br><br>4. Drugs <br>In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor.<br>Michael B Gatch <br>Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the JWH-210 powder highest dose tested (0.5 mg/kg).<br>Figure 1. <br>There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice.<br>Michael B Gat<br><br><br>Separation of compounds was performed on a 2.1 mm×100 mm, 1.7 JWH-210 powder μm particle size ACQUITY Torus™ DIOL analytical column (Waters) with guard cartridge. Measurements were performed by an ACQUITY UPC2 supercritical fluid chromatography system (Waters) coupled with a Xevo TQ-S Triple Quadrupole Mass Spectrometer (Waters). During the death scene examination, multiple cigarette butts without filters were found in an ashtray; also found were alcohol bottles, an unopened box of nebivolol-containing drug, and 18 g of unrecognizable herbal residue in a cigarette box.<br>Data concerning the combined effects of SCRAs and other substances are highly limited, which renders forensic evaluation of possible overdose cases difficult . The threshold SCRA concentration for fatal overdose can be estimated ng/mL level (0.37–4.1 ng/mL according to the reported cases) in cases in which 1.5–2.5 g/L of ethanol is present in the blood. The victims were brothers who were both found deceased after consuming 4F-MDMB-BINACA and ethanol. These confusing shorter names were not scientifically adopted but were used by websites selling the drugs to the public. Monitoring metabolism of synthetic cannabinoid 4F-MDMB-BINACA via high-resolution mass spectrometry assessed in cultured hepatoma cell line, fungus, liver microsomes and confirmed using urine samples. This article does not contain any studies with human participants or animals performed by any of the author

DamonAngas210 at 08:08, 18 May 2026

2026-05-18T08:08:58Z

← Older revision		Revision as of 08:08, 18 May 2026
Line 1:		Line 1:
	In the present study~~, we performed various methods based on animal behavioral testing including FOB test~~ for ~~general behavioral observation~~, ~~rotarod test, locomotor~~ activity ~~test for motor~~ function ~~evaluation,~~ and ~~water~~-~~maze test for learning~~/~~memory evaluation~~. ~~Known for its stability~~ and ~~consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory~~-~~based analytical studies~~. ~~In this study~~, ~~histopathological evaluation was performed~~ to ~~confirm the possibility~~ of ~~neurotoxicity~~ of the tested ~~substances by hematoxylin and eosin staining method from collected brain samples. In~~ the present study~~, we evaluated the neurotoxicity of two~~ synthetic cannabinoids (~~JWH-081 and JWH-210~~) ~~through observation~~ of ~~various behavioral changes~~ and ~~analysis~~ of ~~histopathological changes using experimental mice with various doses (0~~.~~1, 1, 5~~ mg/kg~~). Selecting powder JWH-210 demands careful evaluation of purity, legality,~~ and ~~supplier credibility~~. ~~Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc~~<br><br><br>§ (~~3) of the Hungarian act of Forensic Experts (2016.XXIX~~), ~~the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate~~ that ~~the simultaneous~~ intoxication of SCRA ~~and ethanol directly and exclusively caused the death of the two victims. The victims did~~ not ~~have any significant diseases that could have contributed to the outcome. Very limited data are~~ available ~~in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol~~. ~~Several case reports describe~~ that the ~~presence~~ of ~~a little ng~~/~~mL (~~0~~.37–4.1~~) ~~of SCRAs~~ and ~~a high—but not lethal—concentration of ethanol~~ (1~~.45–2.~~7 ~~g/L~~) ~~directly~~ and ~~exclusively contributed to the death of the victim [24–27] (Table 2)~~. ~~The fact that 4F~~-~~MDMB-BINACA~~ was ~~not~~ detected in ~~postmortem urine samples is partly explained by the high rate~~ of ~~hepatic metabolism of SCRAs [11~~, 14, ~~22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death~~<br><br><br>LC-~~QTOF~~-~~MS represents a significant advancement in the field~~ of ~~drug detection~~, ~~offering higher sensitivity~~, ~~specificity~~, and ~~a broader spectrum of detectable substances~~. ~~Despite all negative results in the point-of-care test for recreational drugs~~, ~~the liquid chromatography-quadrupole time-of~~-~~flight mass spectrometry~~ (~~LC-QTOF-MS~~) ~~analysis showed that~~ the ~~liquid~~ of ~~the~~ e-~~cigarette contained ADB-BUTINACA~~, ~~a synthetic cannabinoid~~. ~~We report a 27-year-old man who~~ was ~~admitted~~ to the ~~emergency room because of sudden click through~~ the ~~following article headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available~~.<br>Data availability <br>~~When clinical presentation and/or initial DOA testing results are inconclusive~~, ~~additional testing with LC~~-~~QTOF~~-~~MS can be valuable~~ and is ~~recommended~~. ~~SCRAs and other NPS may not be detected by point-~~of~~-care~~ DOA ~~tests~~. ~~In this~~ case, the ~~point~~-of~~-care DOA urine screening was not able to detect~~ the ~~synthetic cannabinoid ADB-BUTINAC~~<br><br>The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human<br><br>~~<br>Due~~ to ~~the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According~~ to ~~the reported cases and reviews~~ of ~~the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F~~-~~MDMB-BINACA in the postmortem blood was 2.50~~ and ~~2.34 ng/mL~~, ~~and blood alcohol concentration was 2.11 and 2.49 g/L~~, ~~respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA~~ and ~~ethanol.<br>Fig. 2. <br>4F-~~MDMB-~~BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB~~-~~BINACA ester hydrolysis metabolite~~ (~~B22~~). ~~Data obtained from~~ the ~~twenty urine samples were retrospectively analysed and processed using TraceFinder software~~ based on the ~~identification criteria~~ of ~~mass errors less than ±~~ 5 ~~ppm for full MS peaks~~ and ~~MS/MS peaks from the theoretical mass and matching~~ of ~~MS/MS spectra. The mixture was vortex~~-~~mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation~~, ~~the mixture was cooled at room temperature, and 150 µL~~ of ~~purified water was added~~. ~~High~~-~~resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated~~ in ~~both positive~~ and ~~negative ion modes, to determine accurate masses of the metabolites~~. ~~Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC~~-~~C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA)~~.<br>~~Fig. 1.~~ <br>~~This outcome was anticipated since CES-mediated hydrolysis is commonly [https://cannabinoidsrc4f-adb.com/ click through~~ the following ~~article] reported as the major metabolic pathway among the SCBs impacting the terminal ester group~~ . ~~Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m~~/~~z 350). Both ester hydrolysis followed by oxidative defluorination~~ to ~~butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table~~ 2). ~~A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m~~/~~z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite~~.~~<br>Fungus C. elegans <br>Concentrations of 4F-MDMB-BINACA in~~ the ~~postmortem blood samples were 2.50~~ and 2.~~34 ng~~/~~mL, which are~~ in ~~line with published~~ data. ~~Although~~ the ~~lethal dose of 4F-MDMB-BINACA is unknown~~, ~~its concentration in postmortem blood samples~~ was ~~found to range~~ between ~~0.10~~ and 2.~~90 ng~~/mL . ~~In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than~~ 1 ng/~~mL . Concentrations~~ of ~~SCRAs in postmortem cases cover a wide range ; however, some reports~~ of ~~survival have also been published—even at relatively high blood SCRA concentrations [19, 20~~		All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were [https://cannabinoidsrc4f-adb.com/ find more] observed between 0–30 min. Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/k<br><br>4. Drugs <br>Short-onset, short-acting compounds have a greater abuse liability, and long-acting compounds pose problems of long-acting adverse effects and interactions with other drugs. The duration of action of the synthetic cannabinoids tested using the 8-h protocol have varied widely, with some producing a duration of action no longer than 1 h, others producing a duration of action between 1–2 h, and others lasting more than 2 h. There seems to be a trend of newer synthetic cannabinoids being more potent than earlier compounds. All of the compounds tested in the present study depressed locomotor activity as is typical for other synthetic cannabinoids (see review by Wiley et al., 2017). Average horizontal activity counts/10 min as a function of time (10 min bins) and dose. Depressant effects of 1.33 mg/kg were observed within 10 min following administration and peak depressant effects were observed between 0–30 min.<br>Michael B Gat<br><br><br>As synthetic cannabinoid receptor agonists (SCRA) are gaining popularity globally, clinicians have to understand that intoxication caused by vaping SCRA is not detected by commonly available tests. He confirmed that he had been vaping an electronic cigarette (e-cigarette) earlier that day just before the onset of his symptoms. Metabolic acidosis (1/3, 0/7) and respiratory acidosis (1/3, 0/7), All 10 patients recovered with supportive care, including intubation and ventilation for one case. In 3 cases ADB-BUTINACA was the only substance detected, while in seven other substances of misuse were also detected including other SCRA, opioids, benzodiazepines cocaine and pregabali<br><br><br>A limitation of this case report is that we did not have a urine sample available for additional NPS testing. Point-of-care DOA tests using urine to screen for misuse of multiple substances, regularly include cannabis, amphetamines, cocaine, opioids, benzodiazepines and methadone. THC, methamphetamine, SRCA, lysergic acid diethylamide (LSD), gamma-hydroxybutyrate (GHB) and ketamine are likely to become volatile under the temperature of current e-cigarettes, while crack cocaine is hard to vaporise. A systematic review including data of 114 patients of which the majority was intoxicated due to SCRA smoking revealed that 45 % of the patients who present at the ER after an intoxication due to SCRA smoking recovered within 24 hours .<br>Data availability <br>Moreover, a study conducted in the United Kingdom investigated components of e-liquids in 112 samples originating from prisoners, teenagers and test purchases of commercially available e-cigarettes taken between 2014 and 2021 . This is the first case report that describes the toxicological symptoms of vaping ADB-BUTINACA. Results of the DOA test (including testing for amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opioids, cannabis, tricyclic antidepressants) were available within 30 minutes and were all negative. We report a case of an involuntary intoxication of the SCRA ADB-BUTINACA after vaping. There are several pitfalls in the detection of SCRA in samples taken from the patient.<br>Data availabili<br><br><br>Synthetic cannabinoids have consistently been shown to produce discriminative stimulus effects similar to those find more of Δ9-THC (Bannister and Connor, 2018), and MDMB-FUBINACA fully substituted for Δ9-THC (Gamage et al., 2018). The chemical structures of the recent synthetic cannabinoids are unlike that of Δ9-THC, but are largely based on the structure of older synthetic cannabinoids that are known to have substantial abuse liability (Fig. 1). All 5 compounds decreased locomotor activity and produced discriminative stimulus effects similar to those of Δ9-THC, which suggests they may have abuse liability similar to that of Δ9-THC. Subsequent testing identified 5F-ADB to have been present in a total of ten people who had died from unexplained drug overdoses in Japan between September 2014 and December 2014. AMB-FUBINACA produced tremors and may be of increased risk in human recreational users.<br>Michael B Gatch <br>Duration of the locomotor depression increased over dose from 30 min following 0.1 mg/kg to 2.5 h following 1 mg/kg. Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the highest dose tested (0.5 mg/kg). Figure 1 shows average horizontal activity counts/10 min as a function of time (0–4 h) and dose of Δ9-TH

KerriJarnigan05 at 08:01, 18 May 2026

2026-05-18T08:01:40Z

← Older revision		Revision as of 08:01, 18 May 2026
Line 1:		Line 1:
	~~These synthetic cannabinoids act directly at cannabinoid CB1~~ and ~~CB2 receptors as does Δ9~~-~~tetrahydrocannabinol (Δ9~~-~~THC) found in marijuana~~, ~~but have different chemical structures unrelated~~ to Δ9-~~THC, different metabolism,~~ and ~~often greater toxicity~~ (~~Fantegrossi et al~~., ~~2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3~~ mg/kg~~, 30-min pretreatment~~). 5F-~~MDMB-PINACA (also known as 5F-ADB~~, ~~5F-ADB-PINACA)~~, ~~MDMB~~-~~CHIMICA, MDMB~~-~~FUBINACA~~, ~~ADB-FUBINACA~~, and ~~AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit~~<br><br>~~4. Drugs~~ <br>~~In general,~~ the ~~locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210~~ (~~Gatch et al~~.~~, 2016~~), and ~~5F-AMB produced sustained vocalization~~ and ~~convulsions in rats (Gatch et al~~.~~, 2018)~~. ~~All of the synthetic cannabinoids tested~~ in the ~~present study fully substituted for~~ the ~~discriminative stimulus~~ effects of ~~Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for~~ the ~~30-min period~~ of ~~maximal effect,~~ and ~~planned comparisons were conducted for each dose against~~ the ~~vehicle control using single degree-~~of~~-freedom F tests~~. ~~A two-way analysis~~ of ~~variance, with dose as a between groups factor~~ and ~~time as~~ a ~~within subject factor, was conducted on horizontal activity counts~~/~~10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects~~ and to ~~identify behaviorally~~-~~active dose ranges and times~~ of ~~peak effect. Previous studies have demonstrated~~ that ~~these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at~~ the ~~CB1 receptor.~~<br>~~Michael B Gatch~~ <br>~~Substantial depressant effects were observed within~~ the ~~first 10 min~~, and ~~maximal depression was observed between 0–30 min following administration~~. ~~Tremors were observed 30 minutes following 1 mg/kg AMB~~-~~FUBINACA in 3~~ of ~~8 mice (data not shown). Substantial depressant effects were observed within the first 10 min~~, ~~and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at~~ the ~~[https://cannabinoidsrc4f~~-~~adb.com/ JWH~~-~~210 powder] highest dose tested~~ (~~0.5 mg/kg~~)~~.<br>Figure 1. <br>There is indication~~ that ~~at least some~~ of the ~~first~~-~~generation~~ synthetic ~~cannabinoids act at receptors other than~~ cannabinoid ~~CB1 and CB2 (Wiley et al~~.~~, 2016), and~~ a ~~compound from the present study, 5F~~-~~MDMB~~-~~PINACA,~~ was ~~found~~ to ~~activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all~~ of the ~~compounds tested in the present study (MDMB-PINACA~~, ~~MDMB-CHMICA~~, ~~MDMB-FUBINACA, ADB-FUBINACA~~, and ~~AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al~~.~~, 2015, 2016; Gamage et al~~., ~~2018), which suggests these compounds will produce Δ9~~-~~THC~~-~~like effects, including abuse liability~~. ~~Tremors were~~ not ~~observed following AMB~~-~~FUBINACA during the drug discrimination study~~, ~~but~~ the ~~maximum dose tested~~ was ~~only 0.1 mg/kg~~, ~~which is 10~~-~~fold lower than~~ the ~~dose~~ that ~~produced tremors~~ in ~~the mice.<br>Michael B Gat~~<br><br><br>Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to the reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was 2.50 and 2.34 ng/mL, and blood alcohol concentration was 2.11 and 2.49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol.<br>Fig. 2. <br>4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).<br>Fig. 1. <br>This outcome was anticipated since CES-mediated hydrolysis is commonly ~~JWH~~-~~210 powder~~ reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite.<br>Fungus C. elegans <br>~~Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (~~4F-MDMB-BINACA, 4F-MDMB-~~BUTINACA or 4F-ADB)~~, found in ~~numerous SCB product seizures~~, ~~has been reported by various law enforcement since 2018~~ . ~~However, most~~ of ~~the SCBs are full agonists at CB1 and CB2 receptors~~, ~~having a higher risk~~ of ~~undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists~~ at ~~cannabinoid receptor type 1 (CB1) and type 2 (CB2)~~, ~~where they elicit their main effect~~		In the present study, we performed various methods based on animal behavioral testing including FOB test for general behavioral observation, rotarod test, locomotor activity test for motor function evaluation, and water-maze test for learning/memory evaluation. Known for its stability and consistent composition, this compound is frequently utilized by professionals seeking reliable materials for laboratory-based analytical studies. In this study, histopathological evaluation was performed to confirm the possibility of neurotoxicity of the tested substances by hematoxylin and eosin staining method from collected brain samples. In the present study, we evaluated the neurotoxicity of two synthetic cannabinoids (JWH-081 and JWH-210) through observation of various behavioral changes and analysis of histopathological changes using experimental mice with various doses (0.1, 1, 5 mg/kg). Selecting powder JWH-210 demands careful evaluation of purity, legality, and supplier credibility. Prices for research-grade JWH-210 vary significantly based on quantity, purity, and vendor complianc<br><br><br>§ (3) of the Hungarian act of Forensic Experts (2016.XXIX), the data of the reported case can be utilized freely for scientific and educational purposes without special ethical permission. These results indicate that the simultaneous intoxication of SCRA and ethanol directly and exclusively caused the death of the two victims. The victims did not have any significant diseases that could have contributed to the outcome. Very limited data are available in the scientific literature about the possible effects of the combined consumption of SCRAs and ethanol. Several case reports describe that the presence of a little ng/mL (0.37–4.1) of SCRAs and a high—but not lethal—concentration of ethanol (1.45–2.7 g/L) directly and exclusively contributed to the death of the victim [24–27] (Table 2). The fact that 4F-MDMB-BINACA was not detected in postmortem urine samples is partly explained by the high rate of hepatic metabolism of SCRAs [11, 14, 22], but also suggests that the victims consumed 4F-MDMB-BINACA shortly before their death<br><br><br>LC-QTOF-MS represents a significant advancement in the field of drug detection, offering higher sensitivity, specificity, and a broader spectrum of detectable substances. Despite all negative results in the point-of-care test for recreational drugs, the liquid chromatography-quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) analysis showed that the liquid of the e-cigarette contained ADB-BUTINACA, a synthetic cannabinoid. We report a 27-year-old man who was admitted to the emergency room because of sudden click through the following article headache, nausea, vertigo, red eyes and palpitations. Synthetic cannabinoids are gaining popularity globally and detection is not commonly available.<br>Data availability <br>When clinical presentation and/or initial DOA testing results are inconclusive, additional testing with LC-QTOF-MS can be valuable and is recommended. SCRAs and other NPS may not be detected by point-of-care DOA tests. In this case, the point-of-care DOA urine screening was not able to detect the synthetic cannabinoid ADB-BUTINAC<br><br>The findings produce an apparent paradox, since CPP and self-administration predict with high reliability the likelihood that a compound will be abused by humans, and cannabinoids are well-known to produce active drug-seeking in human<br><br><br>Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to the reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was 2.50 and 2.34 ng/mL, and blood alcohol concentration was 2.11 and 2.49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol.<br>Fig. 2. <br>4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA).<br>Fig. 1. <br>This outcome was anticipated since CES-mediated hydrolysis is commonly [https://cannabinoidsrc4f-adb.com/ click through the following article] reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite.<br>Fungus C. elegans <br>Concentrations of 4F-MDMB-BINACA in the postmortem blood samples were 2.50 and 2.34 ng/mL, which are in line with published data. Although the lethal dose of 4F-MDMB-BINACA is unknown, its concentration in postmortem blood samples was found to range between 0.10 and 2.90 ng/mL . In SCRA-related cases in which the deceased suffered from heart disease, the SCRA concentration in the postmortem blood was less than 1 ng/mL . Concentrations of SCRAs in postmortem cases cover a wide range ; however, some reports of survival have also been published—even at relatively high blood SCRA concentrations [19, 20

KerriJarnigan05: Created page with "These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHI..."

2026-05-18T07:56:05Z

Created page with "These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHI..."

New page

These synthetic cannabinoids act directly at cannabinoid CB1 and CB2 receptors as does Δ9-tetrahydrocannabinol (Δ9-THC) found in marijuana, but have different chemical structures unrelated to Δ9-THC, different metabolism, and often greater toxicity (Fantegrossi et al., 2014). Discriminative stimulus effects were tested in rats trained to discriminate Δ9-tetrahydrocannabinol (3 mg/kg, 30-min pretreatment). 5F-MDMB-PINACA (also known as 5F-ADB, 5F-ADB-PINACA), MDMB-CHIMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA (also known as FUB-AMB, MMB-FUBINACA) were tested for in vivo cannabinoid-like effects to assess their abuse liabilit 4. Drugs In general, the locomotor depressant and discriminative stimulus effects have been observed at doses that do not produce adverse effects, although tremors were observed upon handling in mice that received JWH-210 (Gatch et al., 2016), and 5F-AMB produced sustained vocalization and convulsions in rats (Gatch et al., 2018). All of the synthetic cannabinoids tested in the present study fully substituted for the discriminative stimulus effects of Δ9-THC. Subsequently, a one-way analysis of variance was conducted on horizontal activity counts for the 30-min period of maximal effect, and planned comparisons were conducted for each dose against the vehicle control using single degree-of-freedom F tests. A two-way analysis of variance, with dose as a between groups factor and time as a within subject factor, was conducted on horizontal activity counts/10 min interval. Locomotor activity in mice was tested to screen for locomotor depressant effects and to identify behaviorally-active dose ranges and times of peak effect. Previous studies have demonstrated that these compounds have chemical structures similar to synthetic cannabinoids known to have substantial abuse liability and act at the CB1 receptor. Michael B Gatch Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 0–30 min following administration. Tremors were observed 30 minutes following 1 mg/kg AMB-FUBINACA in 3 of 8 mice (data not shown). Substantial depressant effects were observed within the first 10 min, and maximal depression was observed between 10–40 min and lasted up to 2.5 to 3 h at the [https://cannabinoidsrc4f-adb.com/ JWH-210 powder] highest dose tested (0.5 mg/kg). Figure 1. There is indication that at least some of the first-generation synthetic cannabinoids act at receptors other than cannabinoid CB1 and CB2 (Wiley et al., 2016), and a compound from the present study, 5F-MDMB-PINACA, was found to activate midbrain dopamine neurons, but not serotonin neurons (Asaoka et al., 2016). As previously mentioned, all of the compounds tested in the present study (MDMB-PINACA, MDMB-CHMICA, MDMB-FUBINACA, ADB-FUBINACA, and AMB-FUBINACA) act as agonists at CB1 receptors (Banister et al., 2015, 2016; Gamage et al., 2018), which suggests these compounds will produce Δ9-THC-like effects, including abuse liability. Tremors were not observed following AMB-FUBINACA during the drug discrimination study, but the maximum dose tested was only 0.1 mg/kg, which is 10-fold lower than the dose that produced tremors in the mice. Michael B Gat Due to the unknown toxicity of newly emerging SCRAs, forensic assessments of cases involving these substances are challenging. According to the reported cases and reviews of the scientific literature, concurrent ethanol consumption should amplify the toxicity of SCRAs. The concentration of 4F-MDMB-BINACA in the postmortem blood was 2.50 and 2.34 ng/mL, and blood alcohol concentration was 2.11 and 2.49 g/L, respectively. Two fatal cases are reported caused by simultaneous consumption of 4F-MDMB-BINACA and ethanol. Fig. 2. 4F-MDMB-BINACA was hydrolysed via ester hydrolysis forming the 4F-MDMB-BINACA ester hydrolysis metabolite (B22). Data obtained from the twenty urine samples were retrospectively analysed and processed using TraceFinder software based on the identification criteria of mass errors less than ± 5 ppm for full MS peaks and MS/MS peaks from the theoretical mass and matching of MS/MS spectra. The mixture was vortex-mixed and 500 µL of this mixture and 500 µL of methanol were loaded onto the Clean Screen FASt® tube. After incubation, the mixture was cooled at room temperature, and 150 µL of purified water was added. High-resolution QTOF-MS data were acquired on an Agilent 6510 Accurate Mass QTOF mass spectrometer (Agilent Technologies) equipped with dual electrospray ionization (ESI) source operated in both positive and negative ion modes, to determine accurate masses of the metabolites. Chromatographic separation was performed on an Agilent 1290 LC system with a Poroshell 120 EC-C18 analytical column (2.7 μm, 75 × 2.1 mm; Agilent Technologies, Santa Clara, CA, USA). Fig. 1. This outcome was anticipated since CES-mediated hydrolysis is commonly JWH-210 powder reported as the major metabolic pathway among the SCBs impacting the terminal ester group . Glucosides and sulfate metabolites have been reported with other SCBs where C. From these three samples, sample 2 contained only an ester hydrolysis metabolite (m/z 350). Both ester hydrolysis followed by oxidative defluorination to butanoic acid (B4, m/z 362) and monohydroxylation at tert-leucine moiety (B8, m/z 366) metabolites were found in 16/20 urine samples (Table 2). A In-vitro metabolites observed in common among respective seven most abundant metabolites in b C. The product ion detected at m/z 235, indicating loss of sulfate, confirmed the identity of the sulfation metabolite. Fungus C. elegans Methyl (2S)-2-([1-(4-fluorobutyl)-1H-indazole-3-carbonyl]amino)-3,3-dimethylbutanoate (4F-MDMB-BINACA, 4F-MDMB-BUTINACA or 4F-ADB), found in numerous SCB product seizures, has been reported by various law enforcement since 2018 . However, most of the SCBs are full agonists at CB1 and CB2 receptors, having a higher risk of undesirable side effects when compared to THC which is a partial agonist . Synthetic cannabinoids (SCBs) are agonists at cannabinoid receptor type 1 (CB1) and type 2 (CB2), where they elicit their main effect